Login Register Cart 0
Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Has the Time Come to Employ Population and Individual Bioequivalence for the Evaluation of Generics?

Author(s): Francis Micheal*, Mohanlal Sayana, Rajendra Prasad and Balamurali Musuvathi Motilal

Volume 21, Issue 2, 2020

Page: [112 - 125] Pages: 14

DOI: 10.2174/1389200221666200401105119

Price: $65

Abstract

Background: Bioequivalence studies are a vital part of drug development. The average bioequivalence approach is the standard method of assessment to conclude whether the generic product is bioequivalent to the innovator product. Of late, debates are on whether the average bioequivalence approach adequately addresses drug interchangeability as it considers only population mean for the evaluation especially when highly variable drug products and narrow therapeutic index drugs are dealt with. Hence, the alternative approaches like population bioequivalence and individual bioequivalence assessment approaches emerge as they consider inter/intra-subject variance and subject- by-formulation variance along with population mean.

Objectives: The objective of the study was to apply different bioequivalence assessment approaches in a replicate bioequivalence study to evaluate the drug interchangeability.

Methods: This was an open-label, single-dose, randomized, balanced, two-treatment, three-period, three-sequence, partial replicate crossover bioequivalence study of omeprazole enteric-coated tablet 20 mg conducted on 48 normal healthy subjects under fed conditions. The plasma concentration of omeprazole was analyzed by a validated bioanalytical method to determine the pharmacokinetic and statistical parameters to assess average bioequivalence, population bioequivalence, and individual bioequivalence.

Results: In this study, test formulation was shown to be bio-inequivalent to the reference formulation by average bioequivalence, population bioequivalence, and individual bioequivalence approaches.

Conclusion: The outcome of the evaluation clearly states that the bioequivalence outcome of all these approaches are the same. Obviously, it does not mean that these three approaches provide the same outcome though the consideration of variances varies. Certainly, population bioequivalence and individual bioequivalence approach will be more accurate for the assessment of drug interchangeability.

Keywords: Average bioequivalence, population bioequivalence, individual bioequivalence, prescribability, switchability, 95% upper confidence bound, omeprazole, drug interchangeability.

« Previous Next »
Graphical Abstract

[1]
Chow, S.C. Bioavailability and bioequivalence in drug development. Wiley Interdiscip. Rev. Comput. Stat., 2014, 6(4), 304-312.
[http://dx.doi.org/10.1002/wics.1310] [PMID: 25215170]
[2]
Straka, R.J.; Keohane, D.J.; Liu, L.Z. Potential clinical and economic impact of switching branded medications to generics. Am. J. Ther., 2017, 24(3), e278-e289.
[http://dx.doi.org/10.1097/MJT.0000000000000282] [PMID: 26099048]
[3]
van Gelder, T.; Gabardi, S. Methods, strengths, weaknesses, and limitations of bioequivalence tests with special regard to immunosuppressive drugs. Transpl. Int., 2013, 26(8), 771-777.
[http://dx.doi.org/10.1111/tri.12074] [PMID: 23441971]
[4]
Guidance for Industry, determining whether to submit an ANDA or a 505(b)(2) application U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER) 2019.https://www.fda.gov/media/124848/download [Oct 29, 2019]
[5]
https://nckpharma.com/505j-application-505b2-nda-505b1-nda/ [Oct 29, 2019]
[6]
CFR 320.1, Chapter I - Food and drug administration department of health and human services subchapter D- drugs and human use,Bioavailability and bioequivalence requirements https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=320 [Accessed Oct 29, 2019];
[7]
Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence, London Doc. Ref.:CPMP/EWP/QWP/1401/98 Rev. 1/ Corr ** 2010.https://www.ema. europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf [Oct 29, 2019];
[8]
Committee for Medicinal Products for Human Use (CHMP)/ Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) EMA/CHMP/EWP/280/96 2014.https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacokinetic-clinical-evaluation-modified-release-dosage-forms_en.pdf [Oct 29, 2019]
[9]
Multisource (Generic) Pharmaceutical Products; guidelines on registration requirements to establish interchangeability, world health organization mondiale de la sante, working document QAS/04.093/Rev.4, 2005.https://www.who.int/medicines/services/expertcommittees/pharmprep/QAS04_093Rev4_final.pdf [Oct 29, 2019]
[10]
Therapeutic Goods Administration/ Scientific Guidelines https://www.tga.gov.au/clinical-efficacy-and-safety-guidelines [Oct 29, 2019]
[11]
Guidance Documen.Conduct and Analysis of Comparative Bioavailability Studies, Published by authority of the Minister of Health, Adopted Date 2012/02/08, Effective Date 2012/05/22 https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/bioavailability-bioequivalence/conduct-analysis-comparative.html [Oct 29, 2019]
[12]
Medicines Control Council Version 5, 2011.http://www.rrfa.co.za/ wp-content/uploads/2012/11/2.06-Biostudies-Jun11-v5.pdf [Oct 29,2019]
[13]
Guidelines for Bioavailability and Bioequivalence Studies. CDSCO, Directorate General of Health Services, Ministry of HEALTH & Family Welfare, Government of India, New Delhi 2005.https://web.archive.org/web/20140327185526/http://drugscontrol.org/GFBBS.pdf [Oct 29, 2019]
[14]
Guidance for Industry Statistical Approaches to Establishing Bioequivalence. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), January 2001.https://www.fda.gov/media/70958/download [Oct 29, 2019]
[15]
Hauschke, D. Bioequivalence studies in drug development, methods and application; John Wiley & Sons, Ltd, 2007.
[http://dx.doi.org/10.1002/9780470094778]
[16]
Chen, M.; Chow, S.C. Assessing bioequivalence and drug interchangeability. J. Biopharm. Stat., 2017, 27(2), 272-281.
[http://dx.doi.org/10.1080/10543406.2016.1265537] [PMID: 27936343]
[17]
Water, W. Hauck.; Sharon, anderson. Some issues in the design and analysis of equivalence trials. Ther. Innov. Regul. Sci., 1999, 33(1), 109-118.
[18]
Henderson, J.D.; Esham, R.H. Generic substitution: issues for problematic drugs. South. Med. J., 2001, 94(1), 16-21.
[http://dx.doi.org/10.1097/00007611-200194010-00003] [PMID: 11213935]
[19]
Wijnand, H.P. Assessment of average, population and individual bioequivalence in two- and four-period crossover studies. Comput. Methods Programs Biomed., 2003, 70(1), 21-35.
[http://dx.doi.org/10.1016/S0169-2607(02)00019-6] [PMID: 12468124]
[20]
Francis, M. Balamurali musuvathi motial.; Mohanlal, sayana. Curr. Drug Metab., 2019, 20(1), 835-844.
[21]
Zariffa, N.M.D.; Patterson, S.D. Population and individual bioequivalence: lessons from real data and simulation studies. J. Clin. Pharmacol., 2001, 41(8), 811-822.
[http://dx.doi.org/10.1177/00912700122010708] [PMID: 11504268]
[22]
Endrenyi, L.; Midha, K.K. Individual bioequivalence--has its time come? Eur. J. Pharm. Sci., 1998, 6(4), 271-278.
[http://dx.doi.org/10.1016/S0928-0987(97)10021-5] [PMID: 9795081]
[23]
Tothfalusi, L.; Endrenyi, L. Limits for the scaled average bioequivalence of highly variable drugs and drug products. Pharm. Res., 2003, 20(3), 382-389.
[http://dx.doi.org/10.1023/A:1022695819135] [PMID: 12669957]
[24]
Francis, M. Balamurali, MM.; Mohanlal, Sayana.; Rajendra, Prasad, M. Assessment of comparative bioavailability of Itraconazole capsule 100 mg under fasting conditions by average bioequivalence (ABE), population bioequivalence (PBE) and individual bioequivalence (IBE) approaches. Int. J. Res. Pharm. Sci, 2019, 10(4), 3339-3345.
[25]
Barrett, J.S.; Batra, V.; Chow, A.; Cook, J.; Gould, A.L.; Heller, A.H.; Lo, M.W.; Patterson, S.D.; Smith, B.P.; Stritar, J.A.; Vega, J.M.; Zariffa, N. PhRMA perspective on population and individual bioequivalence. J. Clin. Pharmacol., 2000, 40(6), 561-570.
[http://dx.doi.org/10.1002/j.1552-4604.2000.tb05980.x] [PMID: 10868305]
[26]
Idkaidek, N.M.; Al-Ghazawi, A.; Najib, N.M. Bioequivalence evaluation of two brands of amoxicillin/clavulanic acid 250/125 mg combination tablets in healthy human volunteers: use of replicate design approach. Biopharm. Drug Dispos., 2004, 25(9), 367-372.
[http://dx.doi.org/10.1002/bdd.422] [PMID: 15495146]
[27]
Chow, S.C.; Shao, J.; Wang, H. Statistical tests for population bioequivalence. Stat. Sin., 2003, 13, 539-554.
[28]
Francis, M. Balamurali, MM.; Mohanlal, Sayana.; Rajendra Prasad, M. Assessment of comparative bioavailability of Itraconazole capsule 100mg in healthy subjects under fed conditions by using multiple bioequivalence approaches. J. Pharm. Sci. & Res, 2017, 9(12), 2669-2674.
[29]
Meredith, P. Bioequivalence and other unresolved issues in generic drug substitution. Clin. Ther., 2003, 25(11), 2875-2890.
[http://dx.doi.org/10.1016/S0149-2918(03)80340-5] [PMID: 14693311]
[30]
Food and Drug Administration/ Draft Guidance. Average, Population and Individual Approaches to Establishment Bioequivalence., CDER,Food and Drug Administration: Rockville, MD, . 1999.
[31]
Guidelines for Bioavailability and Bioequivalence Studies. CDSCO, Directorate General of Health Services, Ministry of HEALTH & Family Welfare, Government of India, New Delhi, March 2005.https:// web.archive.org/web/20140327185526/http://drugscontrol.org/GFBBS.pdf [Oct 29, 2019]
[32]
Micheal, F.Balamurali, MM. Drug Interchangeability (Prescribability and Switchability) - Do We Have a Right Tool for the Assessment? J. Pharma. Sci. Res., 2015, 7(11), 1032-1038.
[33]
Francis, Micheal Balamurali, MM. Drug Interchangeability (Prescribability and Switchability) - Do We Have a Right Tool for the Assessment? J. Pharma. Sci. Res., 2010, 7(11), 1032-1038.
[34]
Generic Substitution of Narrow Therapeutic Index Drugs http://www.uspharmacist.com/content/s/78/c/13854 [Oct 29, 2019]
[35]
Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence, London, 20 January Doc. Ref.: CPMP/EWP/QWP/1401/98 2010.https://www.ema.europa. eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf [Oct 29, 2019]
[36]
Chow, S.C. Statistical Methods for Assessment of Individual/Population Bioequivalence 2003.https://pdfs.semanticscholar.org/ 4ae8/83ed90ce3e3959c4e6e395bb733588bf6678.pdf [Oct 29, 2019]
[37]
Pennsylvania Generic Substitution Law http://www.health.pa.gov/ facilities/Consumers,HealthFacilities/HomeHealthServicesand Hospices/DDC/Laws/Narrow.pdf [Oct 29, 2019]
[38]
U.S. Food and Drug Administration. Product Specific Guidance for Warfarin, 2012.http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM201283.pdf [Oct 29, 2019]
[39]
U.S. Food and Drug Administration. Product Specific Guidance for Tacrolimus, 2012.https://www.accessdata.fda.gov/drugsatfda_docs/ psg/Tacrolimus_cap_50708_RV12-12.pdf [Oct 29, 2019]
[40]
U.S. Food and Drug Administration. Product Specific Guidance for Tacrolimus, 2014.https://www.accessdata.fda.gov/drugsatfda_docs/ psg/Tacrolimus_ERcap_204096_RC07-14.pdf [Oct 29, 2019]
[41]
U.S. Food and Drug Administration. Product Specific Guidance for Sirolimus, 2015.https://www.accessdata.fda.gov/drugsatfda_docs/ psg/Sirolimus_oral%20tablet_021110_RV09-15.pdf [Oct 29, 2019]
[42]
U.S. Food and Drug Administration Product Specific Guidance for Carbamazepine, 2015.https://www.accessdata.fda.gov/drugsatfda_ docs/psg/Carbamazepine_oral%20suspension_18927_RV03-15.pdf [Oct 29, 2019]
[43]
U.S. Food and Drug Administration Product Specific Guidance for Carbamazepine, 2015.https://www.accessdata.fda.gov/drugsatfda_ docs/psg/Carbamazepine_Oral%20ER%20cap_20712_RV03-15.pdf [Oct 29, 2019]
[44]
U.S. Food and Drug Administration Product Specific Guidance for Dabigatran etexilate mesylate, 2017.https://www.accessdata.fda.gov/ drugsatfda_docs/psg/Dabigatran%20etexilate%20mesylate_oral%20capsule_NDA%20022512_RV05-17.pdf [Oct 29, 2019]
[45]
U.S. Food and Drug Administration Product Specific Guidance for Levothyroxine sodium capsule, 2018.https://www.accessdata.fda.gov/ drugsatfda_docs/psg/Levothyroxine_Sodium%20capsules_NDA%20021924_RC%20Oct%202018.pdf [Oct 29, 2019]
[46]
U.S. Food and Drug Administration Product Specific Guidance for Phenytoin sodium ER capsule, 2014.https://www.accessdata.fda.gov/ drugsatfda_docs/psg/Phenytoin_sodium_ERcap_040298RV12-14.pdf [Oct 29, 2019]
[47]
U.S. Food and Drug Administration Product Specific Guidance for Tacrolimus granules for oral suspension, 2015.http://www.ema. europa.eu/docs/en_GB/document_library/Scientific_guideline/ 2015/10/WC500195127.pdf [Oct 29, 2019]
[48]
U.S. Food and Drug Administration Product Specific Guidance for Sirolimus, 2013.http://www.ema.europa.eu/docs/en_GB/document_ library/Scientific_guideline/2013/11/WC500154323.pdf [Oct 29, 2019]
[49]
U.S. Food and Drug Administration Product Specific Guidance for Progesterone, 2011.https://www.accessdata.fda.gov/drugsatfda_docs/ psg/Progesterone_caps_19781_RC02-11.pdf [Oct 29, 2019]
[50]
U.S. Food and Drug Administration.. Product Specific Guidance for Alendronate Sodium; Cholecalciferol, 2011.https://www.accessdata. fda.gov/drugsatfda_docs/psg/Alendronate_Cholecalciferol_tab_21762_RC4-09.pdf [Oct 29, 2019]
[51]
U.S. Food and Drug Administration Product Specific Guidance for Alendronate Sodium, 2011.https://www.accessdata.fda.gov/ drugsatfda_docs/psg/Alendronate__Sodium_tab_20560_RC1-08.pdf [Oct 29, 2019]
[52]
U.S. Food and Drug Administration Product Specific Guidance for Amlodipine Besylate, 2008.https://www.accessdata.fda.gov/ drugsatfda_docs/psg/Amlodipine_Besylate_tab_19787_RC6-03.pdf [Oct 29, 2019]
[53]
U.S. Food and Drug Administration. Product Specific Guidance for Amlodipine Besylate; Atorvastatin Calcium 2009.https://www. accessdata.fda.gov/drugsatfda_docs/psg/Amlodipine_Besylate;_ Atorvastatin_Calcium_tab_21540_RC5-09.pdf [Oct 29, 2019]
[54]
U.S. Food and Drug Administration Product Specific Guidance for Rabeprazole Sodium DR Capsule, 2014.https://www.accessdata. fda.gov/drugsatfda_docs/psg/Rabeprazole%20sodium_DRcap_204736_RC02-14.pdf [Oct 29, 2019]
[55]
U.S. Food and Drug Administration Product Specific Guidance for Rabeprazole Sodium DR Tablet, 2010.https://www.accessdata.fda. gov/drugsatfda_docs/psg/Rabeprazole_Sodium_DRTab_20973_RC12-10.pdf [June 21, 2019]
[56]
U.S. Food and Drug Administration Product Specific Guidance for Esomeprazole magnesium powder for delayed-release suspension, 2018.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Esomeprazole%20magnesium_oral%20DR%20suspension_NDA%20021957%20and%20022101_RV11-17.pdf [Oct 29, 2019]
[57]
U.S. Food and Drug Administration Product Specific Guidance for Esomeprazole Magnesium Naproxen DR Tablet, 2011.https://www. accessdata.fda.gov/drugsatfda_docs/psg/Esomeprazole_Mag;_ Naproxen_DRtab_22511_RC03-11.pdf [Oct 29, 2019]
[58]
U.S. Food and Drug Administration Product Specific Guidance for Esomeprazole Strontium DR Capsule, 2014.http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM406265.pdf [Oct 29, 2019]
[59]
European Medicines Agency. Committee for Proprietary Medicinal Products (CPMP), Note for Guidance on the Investigation of Bioavailability and Bioequivalence, http://healthtech.who.int/pq/info_ applicants/BE/ emea_bioequiv.pdf2019 [Oct 29, 2019]
[60]
Losec MUPS Tablets 40mg https://www.medicines.org.uk/emc/ product/1374/pil [Oct 29, 2019]
[61]
Losec MUPS 20 mg gastro-resistant tablets https://www.medicines. org.uk/emc/product/1514/smpc [Oct 29, 2019]
[62]
Prilosec OTC https://www.accessdata.fda.gov/drugsatfda_docs/label/ 2019/021229Orig1s033lbl.pdf [Oct 29, 2019]
[63]
Guideline for good clinical practice, E6(R1), ICH Harmonized Tripartite Guideline, 1996 10June;
[64]
ICMR. National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017.https://www.icmr.nic.in/ sites/default/files/guidelines/ICMR_Ethical_Guidelines_2017.pdf [Oct 29, 2019]
[65]
WMA General Assembly, Seoul, October 2008.https://www.wma.net/ policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects [Oct 29, 2019]
[66]
Guidance 15: Biopharmaceutic studies, April 2015.https://www. tga.gov.au/sites/default/files/guidance-15-biopharmaceutic-studies.pdf [Oct 29, 2019]
[67]
Omeprazole DR Tablet 2012.https://www.accessdata.fda.gov/ drugsatfda_docs/psg/Omeprazole_DRtab_022032_RC09-12.pdf [Oct 29, 2019]
[68]
Omeprazole Magnesium DR Tablet 2008.https://www.accessdata.fda. gov/drugsatfda_docs/psg/Omeprazole_Magnesium_DRtabOTC_21229_RC4-06.pdf [Oct 29, 2019]
[69]
Guidance for industry: bioanalytical method validation. U. S. Department of Health and Human Services, Food and Drug Administration,Centre for Drug Evaluation and Research (CDER), Centre for Biologics Evaluation and Research (CBER): May 2018.https://www. fda.gov/media/70858/download [Oct 29, 2019]
[70]
Steinijans, V.W. Some conceptual issues in the evaluation of average, population, and individual bioequivalence. Drug Inf. J., 2001, 35, 893-899.
[http://dx.doi.org/10.1177/009286150103500328]
[71]
Schall, R.; Luus, H.G. On population and individual bioequivalence. Stat. Med., 1993, 12(12), 1109-1124.
[http://dx.doi.org/10.1002/sim.4780121202] [PMID: 8210816]

Rights & Permissions Print Cite
Article Metrics
40
1
© 2024 Bentham Science Publishers | Privacy Policy